Apontis Pharma AG
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, dylipidemia, secondary prophylaxis, and asthma, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. Apont… Read more
Apontis Pharma AG (APPH) - Total Assets
Latest total assets as of June 2025: €43.99 Million EUR
Based on the latest financial reports, Apontis Pharma AG (APPH) holds total assets worth €43.99 Million EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Apontis Pharma AG - Total Assets Trend (2018–2024)
This chart illustrates how Apontis Pharma AG’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Apontis Pharma AG - Asset Composition Analysis
Current Asset Composition (December 2024)
Apontis Pharma AG's total assets of €43.99 Million consist of 52.8% current assets and 47.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 34.8% |
| Accounts Receivable | €108.07K | 0.2% |
| Inventory | €5.47 Million | 12.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €17.65 Million | 39.8% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Apontis Pharma AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Apontis Pharma AG's current assets represent 52.8% of total assets in 2024, a decrease from 54.7% in 2018.
- Cash Position: Cash and equivalents constituted 34.8% of total assets in 2024, up from 25.9% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, a decrease from 43.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 39.8% of total assets.
Apontis Pharma AG Competitors by Total Assets
Key competitors of Apontis Pharma AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Apontis Pharma AG - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Apontis Pharma AG generates 1.09x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Apontis Pharma AG generates $ 1.70 in net profit.
Apontis Pharma AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.82 | 4.25 | 0.74 |
| Quick Ratio | 4.30 | 3.14 | 0.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €17.93 Million | € 20.61 Million | € -4.84 Million |
Apontis Pharma AG - Advanced Valuation Insights
This section examines the relationship between Apontis Pharma AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.90 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | -22.8% |
| Total Assets | €44.37 Million |
| Market Capitalization | $11.70 Million USD |
Valuation Analysis
Below Book Valuation: The market values Apontis Pharma AG's assets below their book value (0.26 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Apontis Pharma AG's assets decreased by 22.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Apontis Pharma AG (2018–2024)
The table below shows the annual total assets of Apontis Pharma AG from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €44.37 Million | -22.77% |
| 2023-12-31 | €57.46 Million | -4.00% |
| 2022-12-31 | €59.85 Million | +10.57% |
| 2021-12-31 | €54.13 Million | +82.32% |
| 2020-12-31 | €29.69 Million | -2.93% |
| 2019-12-31 | €30.59 Million | -12.22% |
| 2018-12-31 | €34.84 Million | -- |